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Abstract 
 
Purpose: Radiotherapy-induced gut toxicity (RIGT) is a debilitating effect of radiotherapy for cancer, 
often resulting in significant diarrhoea and pain. Previous studies have highlighted roles of the intestinal 
microvasculature and matrix metalloproteinases (MMPs) in the development of RIGT. We hypothesized 
vascular mediators would be significantly altered in a dark agouti (DA) rat model of RIGT. Additionally, 
we aimed to assess the effect of MMP-2 and -9 inhibition on the response of tumour-associated 
microvascular endothelial cells (TAMECs) to radiation.  
Methods: Dark Agouti (DA) rats were administered 2.5 Gy abdominal irradiation (3 times/week over 6 
weeks). Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), von 
Willebrand factor (VWF), angiostatin, and endostatin expression was assessed at 3, 6 and 15 weeks. 
Additionally, DA rat mammary adenocarcinoma tumour-associated microvascular endothelial cells 
(TAMECs) were used to assess the effects of radiation (12 Gy) and the MMP inhibitor SB-3CT on 
MMP, VEGF, and TGFβ expression, and cell viability.  
Results: VEGF mRNA expression was significantly increased in the colon at week 15 (p = 0.0012), and 
TGFβ mRNA expression was significantly increased in both the jejunum and colon at week 3 (p = 
0.0280, and p = 0.0310, respectively). Endostatin immunostaining was significantly increased at week 3 
(p = 0.0046), and angiostatin at 3 and 6 weeks (p = 0.0022, and p = 0.0135, respectively). MMP-2 and -
9 mRNA and total protein levels were significantly increased following irradiation of TAMECs. Although 
this increase was significantly attenuated by SB-3CT, it did not significantly alter endothelial cell viability 











Conclusions: Findings of this study support the involvement of VEGF, TGFβ, angiostatin, endostatin, 
and MMP-2 in the pathobiology of RIGT. However, the relationship between these mediators is 
complex and needs further investigation to improve understanding of their therapeutic potential in 












Radiotherapy-induced gut toxicity (RIGT), estimated to affect 60-80% of patients receiving radiotherapy 
for abdominal or pelvic tumours, induces debilitating symptoms including, but not limited to, diarrhoea, 
pain, rectal bleeding, and incontinence (Theis et al. 2010; Shadad et al. 2013; Hauer-Jensen et al. 
2014). RIGT is often divided into acute and chronic toxicity, with acute changes involving 
histopathological damage to villi and crypts, and chronic involving reactive fibrotic thickening (Yeoh et 
al. 2007; Theis et al. 2010). Previous research has suggested the involvement of the intestinal 
microvasculature in the development of RIGT, and several mediators have been investigated (Kruse et 
al. 2004; Yeoh et al. 2007; Stansborough et al. 2017). NFκB, proinflammatory cytokines, and matrix 
metalloproteinases (MMPs) are all upregulated in the intestine following radiation, and have 
downstream effects on vascular mediators such as vascular endothelial growth factor (VEGF), 
transforming growth factor beta (TGFβ), von Willebrand factor (VWF), and the antiangiogenic mediators 
endostatin and angiostatin (Stansborough et al. 2016). Whilst a link has been proposed in RIGT 
(Stansborough et al. 2016) there is limited research which has investigated changes in these mediators 
in the intestinal microvasculature during a fractionated radiation schedule.  
Our previous studies have shown the intestinal microvasculature to be involved in RIGT, with 
apoptosis, cytostasis, telangiectasis, and fibrotic thickening occurring early and late following 
fractionated irradiation in dark agouti (DA) rats (Yeoh et al. 2005; Stansborough et al. 2017). In 
addition, several regulators of angiogenesis and vascular physiology including, but not limited to, TGFβ, 
VEGF, and VWF, are known to be altered in the intestine following irradiation (Wang et al. 2001; Wang 
et al. 2002; Milliat et al. 2006; Lenting et al. 2012; Boerma et al. 2013). VEGF, bound to heparin in the 
extracellular matrix, is able to be released by matrix metalloproteinases (MMPs) such as MMP-2, and 
MMP-9 (Carmeliet 2005). The anti-angiogenic mediators angiostatin and endostatin have also been 
shown to increase in response to irradiation of cancer endothelial cells derived from human breast 











formation of these cells, suggesting angiostatin is involved in endothelial regulation following irradiation 
(Oh et al. 2014). Although it appears angiostatin and endostatin are involved in endothelial response to 
irradiation this connection is yet to be explored in RIGT. With the increasing investigation of the 
possible use of anti-angiogenic agents as adjuvant cancer therapies alongside chemotherapy or 
radiotherapy, targeting mediators such as vascular endothelial growth factor (VEGF) and endostatin, 
the role of these mediators in RIGT needs to be further explored. 
Previous research has clearly shown MMPs are involved in RIGT, with MMP-2 in particular shown to be 
significantly increased during RIGT (Strup-Perrot et al. 2006). It has also been hypothesised MMPs are 
involved in microvascular changes and alteration to vascular mediators such as VEGF, TGFβ, and 
VWF in RIGT (Stansborough et al. 2016). MMPs are able to regulate the expression of several of these 
mediators via the degradation of the extracellular matrix (ECM) leading to the release of latent VEGF 
and TGFβ, as well as forming angiostatin and endostatin by cleaving plasminogen and collagen XVIII 
respectively (Sternlicht and Werb 2001; Kalluri 2003; Carmeliet 2005). In degrading the ECM, MMPs 
also promote endothelial migration, proliferation and tube formation (Kalluri 2003). Despite previous 
literature, a direct link has not been established between MMPs and vascular mediator expression 
following radiation, and the effect of these changes on endothelial cells. Thus the present study aimed 
to first confirm the alteration of vascular mediators VEGF, TGFβ, VWF, angiostatin, and endostatin in 
the jejunum and colon following fractionated irradiation in DA rats. We then aimed to determine whether 
inhibition of MMP-2 and -9 with SB-3CT altered endothelial viability and expression of these vascular 
mediators in primary tumour-associated microvascular endothelial cells (TAMECs) derived from DA rat 
mammary adenocarcinomas. TAMECs have been successfully cultured for previous, similar 
experiments, have been phenotyped, and their cultivation in DA rats allows for consistency between 
both components of the study (Bateman et al. 2013). In utilising this primary in vitro model we aimed to 
assess the effects of SB-3CT on tumour endothelial response to irradiation as an initial investigation 











component of the study does not directly translate to RIGT, further studies are required to assess the 
effects of SB-3CT on intestinal endothelium following irradiation. However, results of the present study 
form a foundation for further investigation into the possible use of SB-3CT following irradiation. 
Materials and Methods 
Ethics 
Both studies were conducted in accordance with ethics approved by the Animal Ethics Committees at 
the University of Adelaide (M-041-2006; M-2015-117) and complied with the National Health and 
Medical Research Council (Australia) Code of Practice for Animal Care in Research and Teaching 
(2013). 
Animals and Experimental Design  
Archival tissue from a prior study was utilised in the in vivo component of the present study, and 
experimental design has been previously described (Yeoh et al. 2007; Stansborough et al. 2017). 
Briefly, 30 female Dark Agouti (DA) rats were randomly assigned into two groups, one group receiving 
sham irradiation, and one group receiving a schedule of fractionated irradiation. Both groups of rats 
were anaesthetised using 3% halothane in 100% oxygen and placed into a custom-built container, with 
rats in the treatment group receiving fractionated abdominal irradiation using a Varian Clinac Linear 
Accelerator (Varian Medical Systems, USA) at a dose of 2.5 Gray (Gy) (depth = 3.3 cm, focus-skin 
distance = 130 cm) 3x per week for a total dose of 22.5 Gy in 9 fractions and 45 Gy in 18 fractions over 
3 and 6 weeks, respectively (Yeoh et al. 2007). Rats were killed at 3, 6, or 15 weeks from first 
irradiation dose (n = 5 per time point). Animals were monitored daily and clinical record sheets kept. 
Sections of jejunum (30% of small intestinal length when measured from the pylorus) and colon 
(midlength of the large intestine) were collected as previously described and either formalin-fixed and 











RNA isolation and reverse transcription 
RNA isolation was performed using the Nucleospin® RNA II kit (Macherey-Nagel, Germany) according 
to manufacturers’ protocol. Briefly, 15-20 mg of jejunal and colonic tissue was homogenized using the 
TissueLyser LT (Qiagen) and Nucleospin® RNA II kit reagents (Macherey-Nagel, Germany). The lysate 
was filtered through silica membrane filter columns, desalted, DNA was digested using the DNAse 
reaction mixture, and the silica membrane was washed and dried. RNA was eluted in 60 µl RNase-free 
water. The TAKE3 plate and Synergy MyReader (BioTek) was used to determine RNA concentration 
and purity. RNA (1 µg) was converted to cDNA using the iScript cDNA synthesis (Bio-Rad, USA) 
according to manufacturer’s protocol. The TAKE3 plate and Synergy MyReader was again used to 
determine total cDNA concentration and purity and stock cDNA was diluted to 100 ng/µl with nuclease-
free water.  
Real-time polymerase chain reaction (RT-PCR) 
RT-PCR was performed using the Rotor Gene 3000 (Corbett Research, Sydney, Australia) according to 
manufacturer’s protocol. Reaction mixtures contained 1 µl of cDNA, 5 µl of SYBR green (Applied 
Biosystems, Foster City, CA), 5 µl of nuclease-free water, and 0.5 µl each of 50 pmol/µl forward and 
reverse primers (Table 1). Thermal cycling conditions were as described; denaturation step at 95°C for 
10 minutes, and included 40 cycles at 95°C for 10 s, annealing at 60ºC (VWF, TGFβ, and MMP-2), or 
55ºC (VEGF and MMP-9), for 15 s, and extension and acquiring at 72°C for 20 seconds. 18S was used 
as the housekeeping gene. Primer efficiency was calculated to be between 90-110% for each target 
gene against 18S, and thus the 2-∆∆CT method was used to determine fold change in gene expression 
relative to the housekeeping gene and sham irradiated controls from each time point. 
Immunohistochemistry (IHC) 
Angiostatin and endostatin proteins were visualised by IHC staining in the colon at 3, 6, and 15 week 











used with the EnVision™ FLEX kit for Dako autostainer link systems (Dako, Denmark) as previously 
described (Stansborough et al. 2017). The anti-angiostatin primary antibody (#ab2904, Abcam), and 
anti-endostatin primary antibody (#GTX37706, GeneTex), were used at 6.66 µl/ml and 20 µl/ml, 
respectively. Slides were scanned using the Nanozoomer (Hamamatsu Photonics, Japan) at 40x 
magnification. ImageScope imaging software (Leica Biosystems, Germany) was used to analyse 
angiostatin and endostatin in which percentage of positively stained cells was calculated in the lamina 
propria of each section (averaged from ten randomly selected 40x sections per slide). 
Isolation of tumour-associated microvascular endothelial cells (TAMECs) 
Tumour-associated microvascular endothelial cells were isolated and cultured as previously described 
(Bateman et al. 2013). Briefly, Dark Agouti (DA) rats were injected subcutaneously with DA mammary 
adenocarcinoma cells, and 8 days following, tumours were removed and processed under sterile 
conditions. Surrounding connective tissue was removed and tissue was mechanically disrupted into 1 
mm fragments. The tissue was enzymatically digested in collagenase/dispase (Sigma), and incubated 
with 0.25% trypsin/EDTA (Bateman et al. 2013). Following this, the tissue was centrifuged and 
resuspended in complete growth medium, consisting of supplemented Dulbecco’s Modified Eagle 
Media (DMEM) (28% HEPES buffer, 10% foetal bovine serum (FBS), and 1% L-glutamine, penicillin, 
streptomycin) and filtered through a 100 µm nylon cell strainer (Corning). The resultant suspension was 
added to gelatinised culture flasks and incubated at 37ºC. Tumour-conditioned medium (TCM) was 
added to the TAMECs every 24-48 hours to maintain the endothelial cell culture. Endothelial culture 
was confirmed using immunostaining for endothelial cell markers, as previously described (Bateman et 










Table 1. 18S, VEGF, TGFβ, VWF, MMP-2, and MMP-9 primer sequences 
 
Treatment of TAMECs 
TAMECs at passages 1-2 were detached with trypsin, pelleted, counted, diluted to 1 x 109 cells/mL, and 
split evenly across 4 x 50 ml falcon tubes to represent the four treatment groups (vehicle control, SB-
3CT alone, irradiation alone, and irradiation and SB-3CT combined). Cells were then treated for 24 
hours with either 0.01% DMSO in H20 (vehicle control), or 1 µm SB-3CT. SB-3CT concentration was 
determined by dose response assays (data not shown) and was determined to be within the Ki range of 
inhibiting MMP-2 and MMP-9 (Ki = 14 nM and Ki = 600 nM, respectively), without inhibiting MMP-1, -3, 
or -7 (Ki = 206 µM, Ki = 15 µM, Ki = 96 µM, respectively) (Brown et al. 2000). Following this, falcon 
tubes containing the cells were either sham irradiated, or received 12 Gy gamma irradiation using a 
Cs137 source (IBL-437 Blood Irradiator). Cells were immediately plated according to individual 
experimental conditions. An XTT assay was used to conduct a radiation dose response assay and was 
based on an initial dose range of 0-12 Gy. 12 Gy resulted in a significant decrease in cell viability 
without causing excessive cell death (data not shown). Dosimetry was calculated prior to radiation and 
based on dose rate calculations, calibrated monthly based on degradation constant. 
Protein and RNA extraction from TAMECs 
Following irradiation and/or SB-3CT pre-treatment, TAMECs were seeded into 6-well plates at a cell 
density of 1 x 105 cells/well, and incubated for 24 hours. Following incubation, the media was collected 
and immediately placed on ice. Cells were pelleted and supernatant was collected and stored at -80ºC. 
Lysis buffer (Macherey-Nagel RNA kit) was added to each well. Wells were scraped and cells and 
buffer were collected and disrupted using a 26-gauge needle. β-mercaptoethanol (3.5 µl) was added to 
each tube, vortexed, and further RNA extraction and cDNA conversion was performed according to kit 











MMP 2 and 9 activity assays 
MMP-2 and -9 activity was assessed in supernatant collected from treatment TAMECs, using MMP-2 
and -9 activity assay kits (QuickZyme). Experiments were conducted according to kit protocol. Briefly, 
duplicate diluted samples (1:2 dilution with assay buffer), serially diluted standards, and assay buffer 
controls, were pipetted into the assay plate. The plate was covered and incubated at 4ºC overnight. The 
wells were aspirated and washed with assay buffer, and 50 µl of P-Aminophenyl mercuric acetate 
(APMA) solution (0.5 mM APMA in 0.05% DMSO/assay buffer) was added to wells containing 
standards, and to one of the two duplicate sample wells. Assay buffer was added to the remaining 
sample wells, and detection reagent was added to all wells. The plate was shaken for 20 seconds and 
read at 405 nm to obtain the baseline value, repeated at 6 and 22 hours. Data was analysed by 
subtracting the average blank value from each sample value, creating a standard curve based on the 6 
hour data and plotting the standard concentration against the blank subtracted standard values, 
applying a best-fit curve, and calculating the sample concentrations graphically.    
XTT Assay 
In preparation for XTT assay, 1x105 treated TAMECs were passaged intro 96-well flasks and were left 
to adhere for 24 hours. Following adhering, XTT was performed according to kit protocol (Cell 
Proliferation Kit II (XTT, Sigma), with labelling and electron coupling reagents being prepared 
immediately before removing media from wells, replacing with 100 µl fresh media, and adding 50 µl per 
well of the prepared XTT reagent. The plates were incubated for 6 hours and the plate was read at 490 
nm using the TAKE3 plate and Synergy MyReader.  
Immunocytochemistry (ICC) 
Prior to experimentation of TAMECs, expression of VEGF, VWF, TGFβ, MMP-2, and MMP-9 under 
normal conditions was confirmed using immunocytochemistry (Supplementary Figure 1). Briefly, treated 
TAMECs were passaged into 8-well chamber slides at 2x105 cells/well and left to adhere for 24 hours. 











PBS, incubated with 3% H2O2 in PBS for 5 minutes to reduce non-specific staining, washed, and 
incubated with Triton-X block (100 µl TX-100 and 0.1 g sodium citrate in 100 mL H20) for 8 minutes to 
permeate the cell membrane. The cells were washed and blocked using the normal serum blocking 
reagent (Level 2 USA™ Ultra Streptavidin Detection System kit, Signet Laboratories). Primary 
antibodies (MMP-2; #ab37150, Abcam, MMP-9; #ab58803, Abcam, VEGF; #ab46154, Abcam, VWF; 
#ab6994, Abcam, TGFβ; #ab92486, Abcam) were prepared at previously optimised concentrations of 2 
µl/ml (VWF & MMP-2), 4 µl/ml (VEGF & MMP-9), and 10 µl/ml (TGFβ), and added to each well for 60 
minutes. Cells were washed and a linking reagent (Level 2 USA™ Ultra Streptavidin Detection System 
kit, Signet Laboratories) was applied for 20 minutes. A peroxidase-labelled ultra-streptavidin labelling 
reagent (Signet Laboratories) was applied for 20 minutes, followed by a 1 minute incubation with 
diaminobenzidine (DAB) chromogen in 0.03% hydrogen peroxidase (Signet Laboratories) for 
visualization. Cells were washed, chambers were removed, and slides were counterstained with Lillie 
Meyers haematoxylin (1:10), washed, dehydrated, and coverslipped. 
Statistical Analysis 
Graphpad Prism (version 6) software was used to perform statistical analysis. Normality was 
determined and differences between study group means were analysed using either a one-way or two-
way ANOVA with Sidak’s multiple comparison, or a Kruskal-Wallis test with multiple comparison. 
Asterisks denote significance compared to control at the time point, where * <0.05, ** <0.01, *** <0.001, 












Fractionated irradiation induced changes in weight gain and histopathological damage 
Clinical and histological response to fractionated irradiation for this study has been previously published 
(Stansborough et al. 2017). Briefly, rats receiving fractionated irradiation had significantly lower weight 
gain at week 3 (p = 0.0055), and from week 6 until the completion of the study (p < 0.05), when 
compared to sham irradiated controls (Stansborough et al. 2017). Histopathological damage scoring 
was significantly increased in the colon, but not in the jejunum, at week 3 (p = 0.043). However, 
thickening of the lamina propria, telangiectatic vessel formation, and apoptosis were observed in both 
the jejunum and colon following irradiation (Stansborough et al. 2017). 
VEGF and TGFβ were significantly increased in the colon following irradiation in DA rats 
Despite no significance effect in the jejunum, VEGF mRNA expression was significantly increased in 
the colon at the 15-week time point (p = 0.0012) (Figure 1A + B). TGFβ mRNA expression significantly 
increased in both the jejunum and colon 3 weeks into the radiation schedule (p = 0.0280 and p = 
0.0310, respectively), however was not significantly increased at 6- or 15-weeks in either region (Figure 
1C + D). VWF mRNA expression was not significantly altered at any time point following fractionated 
irradiation in jejunum or colon (Figure 1E + 1F). 
 
Figure 1. VEGF, TGFβ, and VWF expression in the jejunum and colon following fractionated radiation. 
A VEGF mRNA expression in the jejunum following fractionated irradiation B VEGF mRNA expression 
in the colon following fractionated irradiation C TGFβ mRNA expression in the jejunum fractionated 
irradiation. D TGFβ expression in the colon following fractionated irradiation. E Relative mRNA 











colon. Dotted line represents baseline fold change. * = significance compared to control. * <0.05, ** 
<0.01, n=5. Data = mean + standard error of the mean (SEM). 
 
Angiostatin and endostatin immunostaining was significantly increased in the colon following 
fractionated irradiation 
Endostatin was immunostaining significantly increased in the lamina propria of the colon at the 3-week 
time point only (p = 0.0046) (Figure 2A + 2C). Angiostatin immunostaining was significantly increased at 
3- and 6-weeks in the colon lamina propria (p = 0.0022, and p = 0.0135, respectively) (Figure 2B + 2C). 
There were no significant alterations at week 6 or 15.  
 
Figure 2. Endostatin (A) and angiostatin (B) immunostaining in the lamina propria of the colon following 
fractionated irradiation. Cell positivity was calculated using ImageScope software and is determined as 
number of positively stained cells/number of total cells. * denotes significance compared to controls at 
the same time-points, ** <0.01, *** <0.001. Data = mean + SEM, n=5. Scale bars = 20 µm, 40x original 
magnification. 
SB-3CT significantly attenuated the expression of MMP-9 following irradiation of TAMECs 
Relative mRNA expression of MMP-2 was not significantly altered following irradiation of TAMECs 
when compared to controls (p = ns; Figure 3A). However, TAMEC MMP-2 expression following 
irradiation was significantly reduced when pre-treated with SB-3CT, as compared to the radiation only 
group (p = 0.0034) (Figure 3A). MMP-9 mRNA expression was significantly increased following 
irradiation of TAMECs (0.0022). This was significantly attenuated by SB-3CT (p < 0.0001). Despite this 
attenuation of MMP-2 and -9, SB-3CT did not significantly alter cell viability following irradiation, 













Figure 3. MMP-2 (A) and -9 (B) mRNA expression following irradiation of TAMECs, with/without SB-
3CT. Dotted line represents baseline fold change. * = significance compared to control. * <0.05, ** 




SB-3CT significantly attenuated MMP-2 and -9 protein expression following irradiation 
Total protein levels of both MMP-2 and MMP-9 were significantly increased in TAMEC supernatant 
following 12 Gy irradiation (p = 0.046, and p = 0.0401, respectively) (Figure 4A and 4C). This increase 
in total MMP-2 and -9 protein levels was significantly attenuated by the administration of SB-3CT (p = 
0.0119, and p = 0.0209, respectively). The ratio of active: total MMP-2 and -9 were not significantly 
altered following irradiation of TAMECs. However the ratio of active: total MMP-2 was significantly 
increased in the radiation + SB-3CT group, compared to control (p = 0.0379). The ratio of active: total 
MMP-9 was not significantly altered in the radiation + SB-3CT group when compared to all other groups 












Figure 4. Total and active: total ratio of secreted MMP-2 and -9 protein concentration following 
irradiation and MMP inhibition in TAMECs. A Total MMP-2 protein concentration B Ratio of active: total 
MMP-2 protein levels C Total MMP-9 protein concentration D Ratio of active: total MMP-9 protein 
levels. * = significance compared to control. * <0.05. Data = mean + SEM. n = 12 
 
 
SB-3CT did not alter tumour-associated microvascular endothelial cell viability following irradiation 
SB-3CT alone did not significantly alter cell viability; as measured via XTT assay; both irradiation (12 
Gy), and irradiation + SB-3CT significantly reduced cell viability of TAMECs (p = 0.0236, and p = 
0.0003, respectively) (Figure 5). There was no significant difference between the radiation alone, and 
radiation + SB-3CT groups (p = ns; Figure 5).  
 
Figure 5. Cell viability of TAMECs following irradiation and MMP inhibition. * = significance compared 
to control. * <0.05, *** <0.001. Data = mean + SEM. n = 8 
 
VEGF and TGFβ mRNA expression were not significantly altered following irradiation of TAMECs 
RT-PCR was used to assess relative mRNA expression of VEGF and TGFβ following irradiation and 
MMP inhibition in TAMECs. VEGF and TGFβ mRNA expression were unaltered by both irradiation and 












Figure 6. VEGF and TGFβ mRNA expression following irradiation of TAMECs with or without SB-3CT. 
VEGF (A) and TGFβ (B) mRNA expression were not significantly altered following irradiation of 
TAMECs, with or without the presence of SB-3CT. Dotted line represents baseline fold change. Data = 




Although the pathobiology of RIGT is complex, MMPs, the intestinal microvasculature, and associated 
vascular mediators have been shown to be involved (Stansborough et al. 2016). Key findings from this 
study show mRNA expression of VEGF and TGFβ mRNA expression to be significantly increased in 
the intestines following RIGT, and is the first study to show an increase in angiostatin and endostatin 
during RIGT. However, the pattern of upregulation of these mediators was different, occurring at 
different time points and in different intestinal regions. Further, this study assessed the effect of the 
MMP-2 and -9 inhibitor, SB-3CT, on tumour-associated microvascular endothelial cells (TAMECs) 
following irradiation. Both mRNA and protein expression of MMP-2 and -9 were significantly 
upregulated in TAMECs following irradiation, however irradiation did not significantly alter VEGF or 
TGFβ expression in these cells. SB-3CTsignificantly attenuated MMP-2 and -9 mRNA and protein 
expression, however, it did not alter cell viability of TAMECs following irradiation.  
VEGF mRNA expression was significantly increased in the colon at the 15 week time point of the DA rat 
RIGT model. VEGF may have a protective role in gastrointestinal injury, with higher levels of VEGF 
expression correlating with less severe gastric ulcers in murine models of stress-induced gastric 
ulceration (Malara et al. 2005). VEGF has also been shown to regulate normal vasculature in the small 
intestinal villi, with excessive inhibition resulting in regression of normal microvasculature, and reduced 
vascular density (Howdieshell et al. 2001; Saif et al. 2007; Pollom et al. 2015). Clinically, the inhibition 











intestinal villi, and induce epithelial ulceration, supporting a role for VEGF in healing (Mangoni et al. 
2012; Pollom et al. 2015). This regulatory role could be consistent with the timing of VEGF upregulation 
seen in the present study, occurring at the 15 week time-point in the colon only. At this time point, 9 
weeks following the last radiation dose, we have clearly documented and reported on a transition from 
acute to chronic RIGT phenotype which is able to be seen histologically (Stansborough et al. 2017). 
This effect is likely due to alteration of the wound healing process, as well as vascular changes 
resulting in impaired delivery of healing agents to the damaged tissue (Mangoni et al. 2012). This study, 
in combination with findings of previous literature, suggests a role for VEGF in the progression to 
chronic RIGT, possibly playing a part in wound healing following acute RIGT. This potential role of 
VEGF in RIGT needs to be further explored, particularly with the increased study of anti-VEGF as 
adjuvant cancer therapies (Barney et al. 2013; Pollom et al. 2015). When VEGF inhibitors (VEGFIs) are 
combined with radiotherapy, gastrointestinal toxicity has been shown to significantly increase (Barney 
et al. 2013; Pollom et al. 2015). This potential for increased intestinal toxicity needs to be considered 
when determining the clinical potential of these agents. 
Whilst TGFβ expression was significantly increased 3 weeks into the fractionated radiation schedule in 
our rat model of RIGT, consistent with previous literature, it was not significantly upregulated at 6 and 
15 weeks, nor was it altered following irradiation of TAMECs (Richter et al. 1998; Wang et al. 2001). 
The lack of increase in TGFβ at the chronic RIGT time point was somewhat unexpected and in contrast 
with previous literature (Kleifeld et al. 2001). This may be explained by the different models used in the 
study by Wang and colleagues (2001, in which a scrotal hernia is surgically induced and the 
fractionated schedule uses higher doses over a shorter period of time (Wang et al. 2001). Our previous 
studies have shown fibrotic changes to the lamina propria and microvasculature at both the 6 and 15 
week time points (Stansborough et al. 2017). With the complex interactions of TGFβ it is possible that 
the early upregulation of TGFβ, or alterations in the receptors of TGFβ are involved in these fibrotic 











TGFβ being capable of opposing angiogenic effects, highly dependent on conditions and tightly 
regulated in the endothelium by the receptors ALK1 and ALK5 (Goumans et al. 2003). Whilst TGFβ 
binding with ALK5 has an anti-angiogenic effect, inhibiting endothelial cell migration and proliferation, 
ALK1 binding has the opposite effect (Goumans et al. 2003). Thus the ratio of ALK5 to ALK1 seems to 
be key to the functional role of TGFβ in pathological conditions. Further studies, both in vitro and in 
vivo, are needed to investigate the ALK5 to ALK1 ratio and determine where this balance lies in 
endothelial response to irradiation, and during RIGT, in order to determine the role of TGFβ in its 
pathobiology.  
Angiostatin and endostatin immunostaining was shown to be significantly elevated in the lamina propria 
of both the jejunum and colon. This occurred only during the acute time points, with angiostatin 
increasing at 3 and 6 weeks, and endostatin at 3 weeks. The anti-angiogenic mediators angiostatin and 
endostatin, fragments of plasmin and type XVIII collagen, respectively, are responsible for inhibiting 
endothelial cell proliferation and migration, as well as inducing apoptosis in the case of endostatin 
(Ribatti 2009). Endostatin is also known to directly inhibit MMP-2 (Abdollahi et al. 2004). Although this 
current study is the first to assess angiostatin and endostatin in an animal model of RIGT, response of 
angiostatin to radiation has previously been assessed in vitro (14). Oh and colleagues (2014) finding 
angiostatin protein levels to be significantly increased in human breast tissue derived cancer 
endothelial cells following 4 Gy irradiation (Oh et al. 2014). Whilst endostatin has not yet been 
investigated in RIGT, Endostar, a recombinant human endostatin, has been shown to significantly 
decrease MMP-2, -9, -14, and VEGF immunostaining in nasopharyngeal carcinoma xenografts in mice 
following 6 Gy irradiation (Peng et al. 2012). Although the roles of angiostatin and endostatin likely 
differ in normal vs tumour tissue response to radiation, these studies, in combination with the present 












MMP-2 and -9 mRNA and protein expression was significantly increased following irradiation of 
TAMECs. The significant increase in MMP-2 expression is consistent with previous studies finding an 
increase in MMP-2 24 hours following 4 Gy irradiation of human normal endothelial cells and TAMECS 
(NECs and CECs, respectively) derived from breast tissue (Oh et al. 2014). However, the same study 
found MMP-9 not to be altered by irradiation of TAMECs in contrast to the findings of our current study 
(Oh et al. 2014). This is not entirely unexpected, due to species and tissue differences between the two 
studies, with MMP-9 regulation known to depend on cell type (Vincenti and Brinckerhoff 2007). Despite 
these conflicting results, the similarities between the studies highlight a role for MMP-2, in particular, in 
endothelial regulation following irradiation.  
The increase in MMP-2 and -9 expression was also significantly attenuated, both at the mRNA and 
protein level, by the pre-treatment of TAMECs with SB-3CT. SB-3CT is the first mechanism-based 
MMP inhibitor, potently and selectively inhibiting MMP-2 and -9. The effect of SB-3CT is unique in its 
selectivity, as it forms a reactive species within the active sites of MMP-2 and -9 (Kruger et al. 2005) 
and was developed in response to a lack of efficacy of broad-spectrum, synthetic MMP inhibitors when 
used as anti-cancer therapies in clinical trials.  
An unexpected finding in the present study was the significant decrease in mRNA expression of MMP-2 
and MMP-9 following pre-treatment with SB-3CT in TAMECs following irradiation, as the mechanism of 
action of SB-3CT is in inhibiting activation. Additionally, SB-3CT significantly increased MMP-2 activity 
in TAMECs when combined with irradiation, having no effect on activity of MMP-9. The significant 
decrease in proMMP expression by SB-3CT is not unprecedented, with SB-3CT significantly 
decreasing proMMP-9 levels in a mouse model of transient focal cerebral ischemia (37). The study 
hypothesized this decrease was likely due to a positive feedback mechanism between MMP activity 











To our knowledge, this is the first study to assess mRNA expression of MMP-2 and -9 following SB-3CT 
administration. There are endogenous mediators that can be regulated by active MMP-2 and -9, such 
as TGFβ, and pharmacological reagents, such as doxycycline, that have been shown to regulate the 
mRNA expression of MMP-2 and -9 by altering mRNA stability (Yan and Boyd 2007). Whether SB-3CT 
is regulating transcription via a similar process, by affecting the promotor regions of these MMPs, or 
through disruption of a positive feedback mechanism, is unclear. The regulation of mRNA expression of 
both MMP-2 and MMP-9 by SB-3CT should be investigated further and current studies are underway in 
our laboratory. 
The use of a single cell type in this study is a limitation as normal and tumour endothelial cells are 
phenotypically different and subsequently respond differently to irradiation; therefore it is likely that the 
response of normal gut endothelial to SB-3CT would differ to the findings of the present study (Oh et al. 
2014). Thus, in order to further assess the possible effects of MMP inhibition in RIGT, future studies 
assessing SB-3CT in an in vivo model of RIGT are warranted. However, the findings of this study 
highlight a relationship between radiation, MMP expression and tumour endothelium. Due to the 
potential use of specific MMP inhibitors as cancer therapies, and with the involvement of both MMP’s 
and the endothelium in the development and progression of RIGT, the findings of this study highlight 
the need for further research and consideration as to possible dual effects of MMP inhibitors in this 
setting (Strup-Perrot et al. 2006; Angenete et al. 2009; Stansborough et al. 2017). 
Conclusion 
The findings of this study support a role for the vascular mediators VEGF, TGFβ, angiostatin, and 
endostatin in RIGT following fractionated irradiation. Additionally, MMP-2 and -9 were shown to be 
involved in endothelial response to radiation in vitro, however inhibition by SB-3CT did not alter cell 
viability. The findings of the in vitro component of the present study elucidate the effects of SB-3CT on 











MMP expression, and confirm the role of MMP-2 in particular in the endothelial response to irradiation.  
These results highlight the need for further pre-clinical studies to assess the effect of MMP inhibitors 
and anti-angiogenic drugs in RIGT, particularly as these drugs are currently being investigated as 
adjuvant cancer therapies.  
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Supplementary Figure 1. Conformational staining of MMP-2, MMP-9, VWF, and VEGF in tumour-


















































Table 1. 18S, VEGF, TGFβ, VWF, MMP-2, and MMP-9 primer sequences 
 








18S F CATTCGAACGTCTGCCCTAT 
R GTTTCTCAGGCTCCCTCTCC 




VEGF F AGGCGAGGCAGCTTGAGTTA 
R CTGTCGACGGTGACGATGGT 
1601-1766 166 62 
64 
(Zhang et al. 
2014) 
TGFβ F ATGACATGAACCGACCCTTC 
R ACTTCCAACCCAGGTCCTTC 
897-1073 177 60 
60 
(Close et al. 
2005) 
VWF F GCCTCTACCAGTGAGGTTTTGAAG 
R ATCTCATCTCTTCTCTGCTCCAGC 




MMP-2 F CTG ATA ACC TGG ATG CAG TGCT 
R CCA GCC AGT CCG ATT TGA 
2138-2272 135 55  
50 
(Al-Dasooqi 
et al. 2010) 
MMP-9 F AAG CCT TGG TGT GGC ACG AC 
R TGG AAA TAC GCA GGG TTT GC 
760-876 117 56  
52 
(Vikman et 
al. 2007) 
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